melanoma
People whose work centres on melanoma. 24 records carry it: 24 people.
Related tags
24 records
| Cancers | Other tags | ||||
|---|---|---|---|---|---|
Caroline Robert Head of Dermatology Unit, Gustave Roussy; Professor, Paris-Saclay University · Gustave Roussy Led KEYNOTE-006 and COMBI-v, the trials that made pembrolizumab and dabrafenib-trametinib standards in melanoma. | Melanoma | none | immunotherapy, trialist | ||
Dirk Schadendorf Director WTZ Essen; Director, Department of Dermatology · West German Cancer Center (WTZ), University Hospital Essen Melanoma expert who directs the West German Cancer Center at University Hospital Essen. | Melanoma, Cutaneous squamous cell carcinoma, Merkel cell carcinoma | none | leadership, clinician-scientist, immunotherapy | ||
Georgina V. Long Co-Medical Director, Melanoma Institute Australia; Chair of Melanoma Medical Oncology and Translational Research, University of Sydney · Melanoma Institute Australia Melanoma trialist who led COMBI-d, COMBI-AD and NADINA, moving immunotherapy before surgery for stage III disease. | Melanoma | none | neoadjuvant, australia | ||
Howard L. Kaufman Surgical Oncologist, Massachusetts General Hospital; Chief Medical Officer, Ankyra Therapeutics · Massachusetts General Hospital Cancer Center Led OPTiM, the trial that made talimogene laherparepvec the first approved oncolytic virus therapy. | Melanoma, Merkel cell carcinoma | none | immunotherapy, oncolytic-virus | ||
Hussein A. Tawbi Professor and Deputy Chair, Department of Melanoma Medical Oncology, MD Anderson Cancer Center · MD Anderson Cancer Center Led RELATIVITY-047, which made relatlimab the first approved LAG-3 inhibitor, and the trial that showed immunotherapy works in melanoma brain metastases. | Melanoma | none | lag3, brain-metastases | ||
Inge Marie Svane Director, National Center for Cancer Immune Therapy (CCIT-DK), Copenhagen University Hospital Herlev · Herlev Hospital, Copenhagen University Hospital Led the Dutch-Danish trial that proved TIL therapy beats ipilimumab in melanoma, the first randomised win for a cell therapy in a solid tumour. | Melanoma | none | cell-therapy, til | ||
Janja Ocvirk Medical Director (Strokovna direktorica) · Institute of Oncology Ljubljana Medical oncologist and Medical Director of the Institute of Oncology Ljubljana, with research in melanoma and colorectal cancer. | Melanoma, Colorectal cancer | none | leadership, clinician-scientist, colorectal cancer | ||
Jason J. Luke Director, Cancer Immunotherapeutics Center, UPMC Hillman Cancer Center · UPMC Hillman Cancer Center Led KEYNOTE-716, which extended adjuvant pembrolizumab to high-risk stage II melanoma. | Melanoma | none | adjuvant, early-phase | ||
Jean-Jacques Grob Professor of Dermatology, Aix-Marseille University, Hôpital de la Timone · Hôpital de la Timone, Assistance Publique-Hôpitaux de Marseille Marseille dermatologist who led KEYNOTE-629, which established pembrolizumab for advanced cutaneous squamous-cell carcinoma, and who has been a senior investigator on many European melanoma trials. | Advanced cutaneous squamous cell carcinoma, Melanoma, Skin cancer | none | skin, immunotherapy, trialist | ||
Jedd D. Wolchok Meyer Director, Sandra and Edward Meyer Cancer Center, Weill Cornell Medicine · Sandra and Edward Meyer Cancer Center, Weill Cornell Medicine Led CheckMate 067, the trial whose ten-year data showed half of advanced melanoma patients on nivolumab plus ipilimumab are alive. | Melanoma | none | immunotherapy, trialist | ||
Jeffrey E. Gershenwald Surgical oncologist, MD Anderson Cancer Center · MD Anderson Cancer Center Houston surgeon who chaired the melanoma expert panel for the eighth edition of the AJCC staging system, the classification doctors use to describe how far a melanoma has spread. | Stage IIB and IIC melanoma, Stage III melanoma, Melanoma | none | surgery, staging | ||
Jeffrey S. Weber Deputy Director, NYU Langone Perlmutter Cancer Center; Professor of Medicine · Laura and Isaac Perlmutter Cancer Center at NYU Langone Health Led CheckMate 238, which made adjuvant nivolumab standard after melanoma surgery, and co-led the mRNA vaccine trial KEYNOTE-942. | Melanoma | none | adjuvant, vaccine | ||
Jennifer A. Wargo Professor of Genomic Medicine and Surgical Oncology, MD Anderson Cancer Center · MD Anderson Cancer Center Surgeon-scientist who showed the gut microbiome shapes response to immunotherapy and led early neoadjuvant melanoma trials. | Melanoma | none | microbiome, neoadjuvant | ||
John M. Kirkwood Melanoma medical oncologist, UPMC Hillman Cancer Center · UPMC Hillman Cancer Center Pittsburgh melanoma doctor who ran the interferon trials that were the first adjuvant treatment for high-risk melanoma, and later led CheckMate 76K on adjuvant nivolumab for stage II disease. | Stage IIB and IIC melanoma, Stage III melanoma, Melanoma | none | adjuvant, trialist | ||
Mark B. Faries Co-Director, Melanoma Program, The Angeles Clinic and Research Institute, Cedars-Sinai · Cedars-Sinai Cancer Surgeon who led MSLT-II, showing that removing all lymph nodes after a positive sentinel node does not improve melanoma survival. | Melanoma | none | surgery, de-escalation | ||
Michael A. Postow Chief, Melanoma Service, Memorial Sloan Kettering Cancer Center · Memorial Sloan Kettering Cancer Center Led CheckMate 069, the first randomised trial of nivolumab plus ipilimumab, and defines how to manage immunotherapy side effects. | Melanoma | none | immunotherapy, toxicity | ||
Michael B. Atkins Deputy Director, Georgetown Lombardi Comprehensive Cancer Center · Georgetown Lombardi Comprehensive Cancer Center Washington oncologist who led DREAMseq, the trial that showed people with BRAF-mutant melanoma live longer if immunotherapy is given before targeted therapy rather than after. | Advanced melanoma, BRAF V600-mutant melanoma, Melanoma | none | immunotherapy, trialist | ||
Paolo A. Ascierto Director, Unit of Melanoma, Cancer Immunotherapy and Development Therapeutics, Istituto Nazionale Tumori IRCCS Fondazione Pascale, Naples · Istituto Nazionale Tumori IRCCS Fondazione G. Pascale Italian melanoma oncologist who co-led CheckMate 238, CheckMate 067 and the COLUMBUS BRAF/MEK trial. | Melanoma | none | immunotherapy, italy | ||
Paul B. Chapman Melanoma medical oncologist, Memorial Sloan Kettering Cancer Center · Memorial Sloan Kettering Cancer Center New York melanoma doctor who was lead author of BRIM-3, the trial that showed vemurafenib lengthens survival in BRAF-mutant melanoma and launched targeted therapy for the disease. | BRAF V600-mutant melanoma, Melanoma | none | targeted-therapy, trialist | ||
Piotr Rutkowski Surgical oncologist and head of soft tissue, bone sarcoma and melanoma, Maria Skłodowska-Curie National Research Institute of Oncology, Warsaw · Maria Skłodowska-Curie National Research Institute of Oncology Polish surgical oncologist who led the pooled EORTC and SWOG trials showing that imatinib shrinks dermatofibrosarcoma protuberans, a rare skin sarcoma driven by a PDGFB fusion. | Dermatofibrosarcoma protuberans, Melanoma, Gastrointestinal stromal tumour | none | sarcoma, surgery, trialist | ||
Ralf Gutzmer Dermato-oncologist and trial lead German dermato-oncologist who was lead author of IMspire150, the trial that added atezolizumab to vemurafenib and cobimetinib in BRAF-mutant melanoma. | BRAF V600-mutant melanoma, Melanoma | none | immunotherapy, trialist | ||
Reinhard Dummer Professor of Dermatology and Vice Chairman, Department of Dermatology, University Hospital Zurich · University Hospital Zurich / Comprehensive Cancer Center Zurich Swiss dermato-oncologist who led COLUMBUS and the neoadjuvant talimogene laherparepvec studies. | Melanoma, Merkel cell carcinoma | none | targeted-therapy, switzerland | ||
Sapna P. Patel Professor of Medicine and Director of Melanoma Medical Oncology, University of Colorado Cancer Center · University of Colorado Cancer Center Led SWOG S1801, the trial that showed giving pembrolizumab before surgery, not just after, improves outcomes in melanoma. | Melanoma, Uveal melanoma | none | neoadjuvant, swog | ||
Susana Puig Director, IDIBAPS · Hospital Clínic de Barcelona / IDIBAPS Dermatologist and melanoma researcher who directs IDIBAPS, the research institute of Hospital Clínic de Barcelona. | Melanoma, Basal cell carcinoma | none | leadership, clinician-scientist |
